New diabetes drug undergoing trials

Wed, 11 Jun 2008
According to recent reports in the diabetes news, Roche Holding AG are developing a new a groundbreaking new diabetes drug . Currently in clinical trials, experimental diabetes drug taspoglutide has been shown to improve blood sugar control.

Roche are developing the drug in collaboration with Ipsen SA, and the companies say that the once-a-week diabetes medication also causes weight loss . The drug is part of a new class of diabetic medication.

The head of strategic marketing for metabolic diseases at Roche, Luke Miels, was reported as commenting: "It has the potential to have very strong effects on blood glucose and weight loss in an easy, simple device."

Taspoglutide is human-sourced, and will seek to compete with the only GLP-1 on the market, Byetta .
Leave a Comment
Login via Facebook, Yahoo! and Hotmail
or
Have your full say in the Diabetes Forum
Your comments may be moderated. Please report any spam, illegal, offensive or libellous posts.